Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143


Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.

Lun X, Wells JC, Grinshtein N, King JC, Hao X, Dang NH, Wang X, Aman A, Uehling D, Datti A, Wrana JL, Easaw JC, Luchman A, Weiss S, Cairncross JG, Kaplan DR, Robbins SM, Senger DL.

Clin Cancer Res. 2016 Aug 1;22(15):3860-75. doi: 10.1158/1078-0432.CCR-15-1798. Epub 2016 Mar 22.


Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.


High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.

Hothi P, Martins TJ, Chen L, Deleyrolle L, Yoon JG, Reynolds B, Foltz G.

Oncotarget. 2012 Oct;3(10):1124-36.


Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.

Zhao Y, Xiao Z, Chen W, Yang J, Li T, Fan B.

Mol Med Rep. 2015 Aug;12(2):2313-22. doi: 10.3892/mmr.2015.3664. Epub 2015 Apr 22.


Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.

Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, Yip S, Toyota B, Dunn SE.

Oncotarget. 2012 Oct;3(10):1112-23.


A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts.

Han J, Liu L, Yue X, Chang J, Shi W, Hua Y.

Toxicol Appl Pharmacol. 2013 Dec 15;273(3):477-83. doi: 10.1016/j.taap.2013.09.009. Epub 2013 Sep 20.


High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.

Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, Grafström RC, Perälä M, Kallioniemi O.

Clin Cancer Res. 2009 Oct 1;15(19):6070-8. doi: 10.1158/1078-0432.CCR-09-1035. Epub 2009 Sep 29.


p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.

Miao W, Liu X, Wang H, Fan Y, Lian S, Yang X, Wang X, Guo G, Li Q, Wang S.

Mol Med Rep. 2015 Jun;11(6):4165-73. doi: 10.3892/mmr.2015.3255. Epub 2015 Jan 26.


JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.

Okada M, Sato A, Shibuya K, Watanabe E, Seino S, Suzuki S, Seino M, Narita Y, Shibui S, Kayama T, Kitanaka C.

Int J Oncol. 2014 Feb;44(2):591-9. doi: 10.3892/ijo.2013.2209. Epub 2013 Dec 5.


A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.

Huang J, Campian JL, Gujar AD, Tran DD, Lockhart AC, DeWees TA, Tsien CI, Kim AH.

J Neurooncol. 2016 Jun;128(2):259-66. doi: 10.1007/s11060-016-2104-2. Epub 2016 Mar 10.


Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.

Kim JY, Cho Y, Oh E, Lee N, An H, Sung D, Cho TM, Seo JH.

Cancer Lett. 2016 Aug 28;379(1):39-48. doi: 10.1016/j.canlet.2016.05.026. Epub 2016 May 26.


Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.

Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L.

Cell Death Dis. 2014 May 8;5:e1223. doi: 10.1038/cddis.2014.188.


Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.


Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.

Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, Guichet PO, Bian X, Armesilla AL, Darling JL, Wang W.

Br J Cancer. 2012 Oct 23;107(9):1488-97. doi: 10.1038/bjc.2012.442. Epub 2012 Oct 2.


Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer.

Wu X, Xue X, Wang L, Wang W, Han J, Sun X, Zhang H, Liu Y, Che X, Yang J, Wu C.

Eur J Pharmacol. 2018 May 15;827:1-12. doi: 10.1016/j.ejphar.2018.02.039. Epub 2018 Mar 13.


Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors.

Wang NN, Wang LH, Li Y, Fu SY, Xue X, Jia LN, Yuan XZ, Wang YT, Tang X, Yang JY, Wu CF.

Exp Cell Res. 2018 Jan 1;362(1):72-82. doi: 10.1016/j.yexcr.2017.11.004. Epub 2017 Nov 16.


Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.

Bista R, Lee DW, Pepper OB, Azorsa DO, Arceci RJ, Aleem E.

J Exp Clin Cancer Res. 2017 Feb 1;36(1):22. doi: 10.1186/s13046-017-0493-5.


Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid/rhabdoid tumors.

Choi SA, Choi JW, Wang KC, Phi JH, Lee JY, Park KD, Eum D, Park SH, Kim IH, Kim SK.

Neuro Oncol. 2015 Jun;17(6):810-21. doi: 10.1093/neuonc/nou305. Epub 2014 Nov 4.


Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.

Nguyen SA, Stechishin OD, Luchman HA, Lun XQ, Senger DL, Robbins SM, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Sep 15;20(18):4894-903. doi: 10.1158/1078-0432.CCR-13-1856. Epub 2014 Jul 30.


Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram.

Triscott J, Rose Pambid M, Dunn SE.

Stem Cells. 2015 Apr;33(4):1042-6. doi: 10.1002/stem.1956. Review.

Supplemental Content

Support Center